Probuphine® (buprenorphine) implant phase 3 data presented at cpdd annual scientific meeting

Primary efficacy analysis originally presented showed that 96.4 percent of participants in the Probuphine group had at least four months without evidence of drug use versus 87.6 percent in the sublingual buprenorphine group, demonstrating superiority of Probuphine with a p value of 0.034.

Additional sensitivity analyses were conducted to support the robustness of the primary analysis, including the following that were presented at CPDD:

• Statistically significant difference between Probuphine and sublingual buprenorphine in the proportion of subjects for all 6 months without evidence of illicit opioid use (85.7% versus 71.9%, p=0.03). Electricity invented in homes Imputation of all missing values as positive for illicit opioids also demonstrated significant difference (80.5% versus 67.4%, p=0.05).

• A more conservative approach, including the use of supplemental sublingual buprenorphine as non-responders as well as imputing all missing values as positive for illicit opioid use, illustrated similar results for Probuphine and sublingual buprenorphine (63.2% versus 53.9%, p=0.21).

“Non-adherence to medication approved to treat opioid dependence is a leading cause of relapse,” said Frank J. Electricity production in the us Vocci, Ph.D., president and senior research scientist, Friends Research Institute. Electricity news philippines “The study results show that more participants in the implant group sustained at least four months of abstinence from opioids than participants in the sublingual buprenorphine group. Hp gas online registration Implanted just under the skin, Probuphine encourages treatment adherence and adds a new treatment for doctors to utilize to address the opioid dependence epidemic.”

“In the three weeks since we received FDA approval for Probuphine, we have trained over 800 Healthcare Providers who have already begun treating their patients with Probuphine,” said Behshad Sheldon, CEO, Braeburn Pharmaceuticals. Gas and water llc “We recognize the importance to both physicians and patients of this new treatment for opioid dependence and are working to train 5,000 healthcare providers before the end of the year. Electricity quiz for grade 5 We are currently conducting training sessions every weekend to accommodate the interest that has been expressed from qualified healthcare providers.”

Probuphine is the only six-month treatment for opioid dependence and was developed using ProNeura™, Titan Pharmaceuticals’ (NASDAQ: TTNP) continuous drug delivery system that consists of a small, solid implant made from a mixture of ethylene-vinyl acetate (EVA) and buprenorphine. Hp electricity bill payment online The resulting construct is a solid matrix that is placed subdermally, in the upper arm in an outpatient office procedure, and removed in a similar manner at the end of the treatment period. Electricity generation in usa Probuphine implants are 26 millimeters long and 2.5 millimeters in diameter, or about the size of a matchstick. Electricity word search j farkas answers Each implant contains the equivalent of 80 mg of buprenorphine and is placed under the skin in the inner side of the upper arm.

Probuphine is indicated for the maintenance treatment of opioid dependence in patients who have achieved and sustained prolonged clinical stability on low-to-moderate doses of a transmucosal buprenorphine-containing product (i.e., doses of no more than 8 mg per day of Subutex or Suboxone sublingual tablet or generic equivalent).

Probuphine is not appropriate for new entrants to treatment and patients who have not achieved and sustained prolonged clinical stability, while being maintained on buprenorphine 8 mg per day or less of a Subutex or Suboxone sublingual tablet or generic equivalent.

Insertion and removal of PROBUPHINE are associated with the risk of implant migration, protrusion, expulsion resulting from the procedure. Gas efficient cars 2012 Rare but serious complications including nerve damage and migration resulting in embolism and death may result from improper insertion of drug implants inserted in the upper arm. Youtube gas station karaoke Additional complications may include local migration, protrusion and expulsion. Gasco abu dhabi careers Incomplete insertions or infections may lead to protrusion or expulsion.

Because of the risks associated with insertion and removal, PROBUPHINE is available only through a restricted program called the PROBUPHINE REMS Program. Electricity voltage in canada All Healthcare Providers must successfully complete a live training program on the insertion and removal procedures and become certified, prior to performing insertions or prescribing PROBUPHINE implants. Gas 78 facebook Patients must be monitored to ensure that PROBUPHINE is removed by a healthcare provider certified to perform insertions.

• Serious Complications from Insertion and Removal: Rare but serious complications including nerve damage and migration resulting in embolism and death may result from improper insertion of drug implants inserted in the upper arm. Gas house Additional complications may include local migration, protrusion and expulsion. Power per kwh Incomplete insertions or infections may lead to protrusion or expulsion. V gashi halil bytyqi All Healthcare Providers must successfully complete a live training program on the insertion and removal procedures and become certified in the PROBUPHINE REMS program, prior to performing insertions or prescribing PROBUPHINE implants.

• Addiction, Abuse and Misuse: Buprenorphine can be abused in a manner similar to other opioids. Gas stoichiometry lab Monitor patients for conditions indicative of diversion or progression of opioid dependence and addictive behaviors.

• Respiratory and CNS Depression: Significant respiratory depression and death have occurred in association with buprenorphine particularly when taken by the intravenous (IV) route in combination with benzodiazepines or other CNS depressants (including alcohol). Gas key staking Consider dose reduction of CNS depressants when used concomitantly.

• Neonatal Opioid Withdrawal Syndrome: Neonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids during pregnancy.

• Unintentional Pediatric Exposure: In the event an implant protrudes or comes out, keep the implant away from children. Gas definition physics Buprenorphine can cause severe, possibly fatal, respiratory depression in children.

• Risk of Opioid Withdrawal with Abrupt Discontinuation: If treatment is temporarily interrupted or discontinued, monitor patients for withdrawal and treat appropriately.

• Risk of Withdrawal in Patients Dependent on Full Agonist Opioids: Verify that patient is clinically stable on transmucosal buprenorphine and not dependent on full agonists before inserting PROBUPHINE.

• Treatment of Emergent Acute Pain: Treat pain with a non-opioid analgesic whenever possible. Gas monkey monster truck hellcat If opioid therapy is required, monitor patients closely because higher doses may be required for analgesic effect.

• Most common side effects of PROBUPHINE include: headache, insomnia, rhinorrhea, upper respiratory tract infection, nausea, anxiety, back pain, depression, constipation, and vomiting.

Please read the full prescribing information, including boxed warning and Medication Guide, which you can access at https://braeburnpharmaceuticals.com/wp-content/uploads/2016/05/Probuphine-Full-Prescribing-Information.pdf.

About Opioid Use Disorder and Buprenorphine Opioid use disorder is a chronic brain disease and one of the fastest growing public health epidemics in America. Electricity hero names In the U.S., 2.5 million people struggle with opioid addiction and, according to the Centers for Disease Control, 78 people die each day from the disease. Chapter 7 electricity There is a growing body of evidence that opioid addiction is not a choice or a moral failing, but the result of genetic predisposition combined with environmental factors. E85 gasoline Nonetheless, individuals struggling with this disease continue to be stigmatized. Electricity symbols Research has also shown that opioid use disorder is best treated with a combination of medication and psychosocial support. Gas oil ratio chainsaw The majority of individuals with opioid addiction cannot sustain recovery without long-term outpatient medical treatment.

Buprenorphine is a partial opioid agonist, which may help individuals to stop opioid use without experiencing withdrawal symptoms. Grade 6 electricity worksheets Before FDA approval of Probuphine, buprenorphine was only available in oral form which must be taken daily.

Braeburn Pharmaceuticals, an Apple Tree Partners company, is a pill-free pharmaceutical company delivering precision medicine in neuroscience. Power company near me Long-acting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in neurological and psychiatric disorders, which are often complicated by stigma and present significant public health challenges. 7 cases movie Probuphine, Braeburn’s long -acting buprenorphine implant, was approved by the FDA in May 2016. Electricity and magnetism review game Braeburn’s investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Electricity lyrics Braeburn’s pipeline products are at various stages of clinical development and include CAM2038, weekly and monthly subcutaneous injection depot formulations of buprenorphine, being investigated in opioid addiction and pain; a risperidone six-month implant being investigated in schizophrenia; and a novel molecule, ATI-9242, for treatment of schizophrenia. Gastroenteritis More information on Braeburn, can be found at www.braeburnpharmaceuticals.com.

To view the original version on PR Newswire, visit: http://www.prnewswire.com/news-releases/probuphine-buprenorphine-implant-phase-3-data-presented-at-cpdd-annual-scientific-meeting-300285814.html